BioWink, the developer of fertility tracking app Clue, previously obtained seed funding from investors including Dr Kade and Groupe Arnault.
BioWink, the Germany-based women’s health app developer backed by pharmaceutical firm Dr Kade, closed a $7m series A round co-led by venture capital firms Union Square Ventures and Mosaic Ventures on Friday.
Founded in 2013, BioWink has developed an app called Clue that tracks and predicts a woman’s menstrual cycle by analysing data points such as mood, body temperature and sexual activity. The app provides an insight into when the user has an increased chance of conceiving a child.
BioWink…
